EPO and chronic kidney disease: In addition, this study provides for the first time a possible explanation for the increase in blood pressure and CV events observed in patients with CKD or with coronary heart disease who are treated with EPO.1–7 The choice of the population studied was driven by the fact that patients with stage 4 CKD are more likely to receive EPO as part of standard care.